---
title: "JAFRON expects a profit increase, with an estimated annual net profit of 800 million to 860 million yuan, a year-on-year growth of 83% to 97%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/225696349.md"
description: "According to the Zhitong Finance APP, JAFRON disclosed its performance forecast for 2024, estimating a net profit attributable to shareholders of the listed company between 800 million and 860 million yuan, a year-on-year increase of 83% to 97%; the net profit after deducting non-recurring gains and losses is expected to be between 745 million and 805 million yuan, a year-on-year increase of 82% to 97%"
datetime: "2025-01-21T13:23:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/225696349.md)
  - [en](https://longbridge.com/en/news/225696349.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/225696349.md)
---

# JAFRON expects a profit increase, with an estimated annual net profit of 800 million to 860 million yuan, a year-on-year growth of 83% to 97%

According to the Zhitong Finance APP, JAFRON (300529.SZ) disclosed its performance forecast for 2024, estimating a net profit attributable to shareholders of the listed company between 800 million and 860 million yuan, an increase of 83% to 97% year-on-year; the net profit after deducting non-recurring gains and losses is expected to be between 745 million and 805 million yuan, an increase of 82% to 97% year-on-year

### Related Stocks

- [300529.CN](https://longbridge.com/en/quote/300529.CN.md)

## Related News & Research

- [Singapore's OUE strengthens China presence with Shenzhen flagship](https://longbridge.com/en/news/296056716.md)
- [Rhelion signs supply license with Toronto’s UHN for psilocybin trial in Parkinson’s depression](https://longbridge.com/en/news/296134949.md)
- [Naturgy, Greene start pilot plant converting industrial waste, biomass into biomethane](https://longbridge.com/en/news/296196685.md)
- [Photocure Welcomes FDA Proposal to Initiate the Reclassification of Blue Light Cystoscopy Systems from Class III to Class II](https://longbridge.com/en/news/295957543.md)
- [Photocure says FDA proposes shifting blue light cystoscopy systems to Class II from Class III](https://longbridge.com/en/news/295954868.md)